VERNON HILLS, Ill.--(BUSINESS WIRE)--Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced that the U.S. Patent & Trademark Office (USPTO) has issued a Notice of Allowance for a U.S. Patent entitled “Method and Composition for Treating Nodulocystic and Conglobate Acne Vulgaris.” Nodulocystic and conglobate acne are the most severe types of acne vulgaris, affecting some 8-10 million patients in the United States and producing scarring and substantial functional disability as a result of the scars.
Help employers find you! Check out all the jobs and post your resume.
